STOCK TITAN
  1. Home
  2. Sec-filings
  3. MD
  4. [Form 4] Pediatrix Medical Group, Inc. Insider Trading Activity

Pediatrix (NYSE: MD) director gets 7,196 restricted shares in equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Thomas McEachin reported an equity grant and updated holdings. He received a grant of 7,196 restricted shares of Common Stock at a price of $0.00 per share as an annual equity award under the Amended and Restated 2008 Incentive Compensation Plan. These restricted shares will vest on May 7, 2027. Following the grant, he directly holds 18,623 common shares. Separately, a trust titled the Thomas A. McEachin Living Trust dated April 17, 2025 holds 54,646 common shares, for which McEachin and his spouse serve as trustees and beneficiaries.

Positive

  • None.

Negative

  • None.
Insider McEachin Thomas
Role null
Type Security Shares Price Value
Grant/Award Common Stock 7,196 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 18,623 shares (Direct, null); Common Stock — 54,646 shares (Indirect, Thomas A. McEachin Living Trust dated April 17, 2025)
Footnotes (1)
  1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027. The reporting person and his spouse are trustees and beneficiaries of the trust that holds the reported securities.
Restricted share grant 7,196 shares Common Stock annual equity award
Grant price $0.00 per share Restricted share award
Vesting date May 7, 2027 Restricted shares vesting schedule
Direct holdings after grant 18,623 shares Pediatrix Common Stock
Trust holdings 54,646 shares Thomas A. McEachin Living Trust
Restricted shares financial
"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"
Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.
Amended and Restated 2008 Incentive Compensation Plan financial
"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"
annual equity award financial
"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award."
beneficiaries financial
"The reporting person and his spouse are trustees and beneficiaries of the trust"
Beneficiaries are the people or organizations designated to receive benefits, such as money or assets, from a financial arrangement like a trust, insurance policy, or retirement plan. They matter to investors because choosing the right beneficiaries ensures that assets are passed on according to their wishes, providing financial security or support to loved ones when needed. Think of beneficiaries as the intended recipients of a gift or inheritance.
trustees financial
"The reporting person and his spouse are trustees and beneficiaries of the trust"
Trustees are people or a small group legally appointed to hold and manage assets, documents, or obligations on behalf of others and must act in those beneficiaries’ best interests. Think of them as a neutral guardian or custodian who enforces rules, protects assets, and makes decisions that can affect payments, corporate governance, or recovery in a default — all of which directly influence investor returns and risk.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McEachin Thomas
(Last)(First)(Middle)
1301 CONCORD TERRACE
(Street)
SUNRISE FLORIDA 33323
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A(1)7,196A$018,623D
Common Stock54,646IThomas A. McEachin Living Trust dated April 17, 2025(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.
2. The reporting person and his spouse are trustees and beneficiaries of the trust that holds the reported securities.
Remarks:
See Exhibit 24.1 - Power of Attorney
Mary Ann E. Moore, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pediatrix (MD) director Thomas McEachin report in this Form 4?

Director Thomas McEachin reported receiving 7,196 restricted shares of Pediatrix Common Stock as an annual equity award. The filing also updates his direct holdings to 18,623 shares and notes 54,646 shares held indirectly through a living trust.

How many Pediatrix (MD) shares did Thomas McEachin acquire in this grant?

Thomas McEachin acquired 7,196 restricted shares of Pediatrix Common Stock through an equity award. The grant was made at a reported price of $0.00 per share under the company’s Amended and Restated 2008 Incentive Compensation Plan.

When do Thomas McEachin’s new restricted Pediatrix (MD) shares vest?

The 7,196 restricted shares granted to Thomas McEachin will vest on May 7, 2027. Until vesting, they remain subject to the award’s conditions under Pediatrix’s Amended and Restated 2008 Incentive Compensation Plan.

What are Thomas McEachin’s direct Pediatrix (MD) share holdings after this grant?

After the restricted stock grant, Thomas McEachin directly holds 18,623 shares of Pediatrix Common Stock. This reflects his personal ownership, separate from shares held indirectly through the Thomas A. McEachin Living Trust.

How many Pediatrix (MD) shares are held through the Thomas A. McEachin Living Trust?

The Thomas A. McEachin Living Trust dated April 17, 2025 holds 54,646 shares of Pediatrix Common Stock. McEachin and his spouse are trustees and beneficiaries of this trust, which is disclosed as an indirect ownership position.

Is Thomas McEachin’s Pediatrix (MD) Form 4 a market purchase or sale?

The Form 4 reports an equity grant, not a market purchase or sale. McEachin received 7,196 restricted shares as an annual equity award, with no open-market buying or selling activity disclosed in the reported transactions.